Immune Checkpoints Beyond PD-1 Series

Edited by Ana Carrizosa Anderson and Dario Vignali

Inspired by the SITC session “Immune Checkpoints – Beyond PD-1,” JITC continues the impetus of recognizing a widening range of checkpoint targets that are advancing the field forward. Comprised of several authoritative reviews of checkpoints beyond PD-1, this series promotes the tremendous research that is opening new pathways for treating patients with cancer.

LAG-3: from molecular functions to clinical applications

Takumi Maruhashi, Daisuke Sugiura, Il-mi Okazaki, Taku Okazaki

10.1136/jitc-2020-001014

September 13, 2020

TIGIT in cancer immunotherapy

Joe-Marc Chauvin, Hassane M Zarour

10.1136/jitc-2020-000957

September 7, 2020

Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy

Christopher A Chuckran, Chang Liu, Tullia C Bruno, Creg J Workman, Dario AA Vignali

10.1136/jitc-2020-000967

July 15, 2020

Tim-3 finds its place in the cancer immunotherapy landscape

Nandini Acharya, Catherine Sabatos-Peyton, Ana Carrizosa Anderson

10.1136/jitc-2020-000911

June 29, 2020

Lifting the innate immune barriers to antitumor immunity

Carla V Rothlin, Sourav Ghosh

10.1136/jitc-2020-000695

April 8, 2020

Master protocols in immuno-oncology: do novel drugs deserve novel designs?

Luca Mazzarella, Stefania Morganti, Antonio Marra, Dario Trapani, Giulia Tini, Piergiuseppe Pelicci, Giuseppe Curigliano

10.1136/jitc-2019-000475

April 1, 2020

On the mechanism of anti-CD39 immune checkpoint therapy

David Allard, Bertrand Allard, John Stagg

10.1136/jitc-2019-000186

February 24, 2020

Monalizumab: inhibiting the novel immune checkpoint NKG2A

Thorbald van Hall, Pascale André, Amir Horowitz, Dan Fu Ruan, Linda Borst, Robert Zerbib, Emilie Narni-Mancinelli, Sjoerd H. van der Burg, Eric Vivier

10.1186/s40425-019-0761-3

December 1, 2019